VOR

Vor Biopharma Inc. [VOR] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

VOR Stock Summary

Top 10 Correlated Stocks

VOR


In the News

08:00 28 Mar 2024 VOR

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

09:26 28 Mar 2024 VOR

Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study

Vor Bio (VOR) stock gains after dosing the first patient in its phase I/II study of novel cell therapy, VCAR33 (Allogenic), to treat AML. The company extends its cash runway into the second half of 2025.

08:00 28 Mar 2024 VOR

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

08:00 28 Mar 2024 VOR

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

08:00 28 Mar 2024 VOR

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

08:51 28 Mar 2024 VOR

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

08:00 28 Mar 2024 VOR

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

11:29 28 Mar 2024 VOR

How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%

The mean of analysts' price targets for Vor Biopharma Inc. (VOR) points to a 172.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

03:13 28 Mar 2024 VOR

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

Vor Biopharma Inc. is the brainchild of Dr. Siddhartha Mukherjee. Its core idea is to make CAR-Ts safer by using stem cells.

02:08 28 Mar 2024 VOR

Vor Bio Announces Q4 And FY 2022 Results

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, reported its financial results for the three-month period and full year that ended December 31, 2022, and provided a business update. The post Vor Bio Announces Q4 And FY 2022 Results appeared first on Pulse 2.0.

VOR Financial details

Company Rating
Neutral
Market Cap
130.87M
Income
-115.87M
Revenue
0
Book val./share
2.22
Cash/share
2.02
Dividend
-
Dividend %
-
Employees
168
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-1.38
Forward P/E
-1.31
PEG
0.56
P/S
-
P/B
0.89
P/C
1.16
P/FCF
-1.63
Quick Ratio
10.4
Current Ratio
10.69
Debt / Equity
0.24
LT Debt / Equity
0.21
-
-
EPS (TTM)
-1.73
EPS next Y
-1.8
EPS next Q
-0.48
EPS this Y
-23.58%
EPS next Y
4.19%
EPS next 5Y
-16.18%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-20.41%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
82.31%
Inst Trans
0.9%
ROA
-50%
ROE
-52%
ROC
-0.59%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
68.17M
Shs Float
58.94M
-
-
-
-
Target Price
6
52W Range
1.62-6.18
52W High
-60.83%
52W Low
+135.05%
RSI
58
Rel Volume
1.32
Avg Volume
277.01K
Volume
365.98K
Perf Week
30.58%
Perf Month
10.87%
Perf Quarter
19.31%
Perf Half Y
10.87%
-
-
-
-
Beta
-0.388
-
-
Volatility
0.14%, 0.15%
Prev Close
6.36%
Price
2.3505
Change
7.33%

VOR Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.94-1.25-2.06-2.29-1.75
Operating cash flow per share
-0.81-1.05-2.07-2.15-1.49
Free cash flow per share
-0.87-1.17-2.18-2.37-1.51
Cash per share
0.531.46.215.822.04
Book value per share
0.631.396.476.342.24
Tangible book value per share
0.631.396.476.342.24
Share holders equity per share
0.631.396.476.342.24
Interest debt per share
0.050.530.540.950.53
Market cap
457.81M1.3B388.49M263.02M151.18M
Enterprise value
451.34M1.27B286.71M244.22M155.48M
P/E ratio
-39.99-29.98-5.65-2.9-1.28
Price to sales ratio
00000
POCF ratio
-46.45-35.79-5.62-3.09-1.51
PFCF ratio
-43.18-32.11-5.32-2.81-1.49
P/B Ratio
59.9226.911.81.051
PTB ratio
59.9226.911.81.051
EV to sales
00000
Enterprise value over EBITDA
-44.37-29.69-4.24-2.69-1.27
EV to operating cash flow
-45.8-34.96-4.15-2.87-1.55
EV to free cash flow
-42.57-31.36-3.93-2.61-1.53
Earnings yield
-0.03-0.03-0.18-0.35-0.78
Free cash flow yield
-0.02-0.03-0.19-0.36-0.67
Debt to equity
00.380.080.160.24
Debt to assets
00.240.070.130.17
Net debt to EBITDA
0.640.711.510.21-0.04
Current ratio
3.454.8121.1218.069.04
Interest coverage
-17.130070.560
Income quality
0.910.8410.920.85
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.080.110.060.10.01
Capex to revenue
00000
Capex to depreciation
-8.22-6.88-2.72-3.35-0.31
Stock based compensation to revenue
00000
Graham number
3.636.2617.318.099.41
ROIC
-1.44-0.51-0.27-0.28-0.58
Return on tangible assets
-1.16-0.57-0.28-0.3-0.56
Graham Net
0.350.65.424.591.16
Working capital
5.35M38.9M204.25M223.83M125.23M
Tangible asset value
7.64M48.27M216.26M250.61M150.72M
Net current asset value
5.35M21.47M188.07M188.19M81.7M
Invested capital
00.380.080.160.24
Average receivables
00000
Average payables
365.5K1.53M1.95M1.66M1.29M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
2.78K621.32126.772.1985.19
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.130.592.885.064.28
Inventory turnover
00000
ROE
-1.5-0.9-0.32-0.36-0.78
Capex per share
-0.06-0.12-0.12-0.21-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.58-0.4-0.45-0.49-0.39
Operating cash flow per share
-0.46-0.37-0.36-0.41-0.35
Free cash flow per share
-0.47-0.37-0.37-0.42-0.36
Cash per share
5.823.172.792.372.02
Book value per share
6.343.473.052.592.22
Tangible book value per share
6.343.473.052.592.22
Share holders equity per share
6.343.473.052.592.22
Interest debt per share
0.960.550.560.540.53
Market cap
263.02M356.51M207.13M143.33M152.76M
Enterprise value
244.22M352.51M212.43M134.9M157.06M
P/E ratio
-2.87-3.37-1.73-1.08-1.45
Price to sales ratio
00000
POCF ratio
-14.34-14.69-8.59-5.14-6.36
PFCF ratio
-14.09-14.63-8.45-5.05-6.33
P/B Ratio
1.051.551.010.821.01
PTB ratio
1.051.551.010.821.01
EV to sales
00000
Enterprise value over EBITDA
-10.14-11.92-7.33-3.82-5.77
EV to operating cash flow
-13.31-14.53-8.81-4.84-6.54
EV to free cash flow
-13.08-14.47-8.67-4.76-6.51
Earnings yield
-0.09-0.07-0.14-0.23-0.17
Free cash flow yield
-0.07-0.07-0.12-0.2-0.16
Debt to equity
0.160.170.180.210.24
Debt to assets
0.130.140.150.160.17
Net debt to EBITDA
0.780.14-0.180.24-0.16
Current ratio
18.0617.2415.0510.699.04
Interest coverage
24.4615.3000
Income quality
0.770.850.80.840.91
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.0200.020.020
Capex to revenue
00000
Capex to depreciation
-0.51-0.11-0.130.33-0.12
Stock based compensation to revenue
00000
Graham number
9.095.595.545.344.4
ROIC
-0.07-0.09-0.12-0.15-0.13
Return on tangible assets
-0.08-0.1-0.12-0.15-0.13
Graham Net
4.592.462.091.651.15
Working capital
223.83M204.32M178.68M149.05M125.23M
Tangible asset value
250.61M230.22M204.45M174.78M150.72M
Net current asset value
188.19M169.58M144.86M116.2M81.7M
Invested capital
0.160.170.180.210.24
Average receivables
00000
Average payables
1.3M2.49M2.43M1.48M1.06M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
52.13103.74120.1956.482.23
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
1.730.870.751.61.09
Inventory turnover
00000
ROE
-0.09-0.11-0.15-0.19-0.17
Capex per share
-0.010-0.01-0.010

VOR Frequently Asked Questions

What is Vor Biopharma Inc. stock symbol ?

Vor Biopharma Inc. is a US stock , located in Cambridge of Ma and trading under the symbol VOR

Is Vor Biopharma Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $6. The lowest prediction is $6 and the highest is $6

What is VOR stock prediction ?

What is Vor Biopharma Inc. stock quote today ?

Vor Biopharma Inc. stock price is $2.3505 today.

Is Vor Biopharma Inc. stock public?

Yes, Vor Biopharma Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap